I totally agree. The fact that patients would not
Post# of 157598

This seems like the same old same old. Even beginning this protocol with a 350 mg dose delays a true assessment of the benefits that leronlimab might provide. Not making an ICI available to those who respond with elevating PD-L1 handicaps the trial and and is not in the best interest of the patients.

